> Details

Lim, Li Yan; Miao, Hui; Lim, Joline S. J.; Lee, Soo Chin; Bhoo‐Pathy, Nirmala; Yip, Cheng Har; Taib, Nur Aishah B. M.; Chan, Patrick; Tan, Ern Yu; Lim, Swee Ho; Lim, Geok Hoon; Woo, Evan; Tan, Yia Swam; Lee, Jung Ah; Wong, Mabel; Tan, Puay Hoon; Ong, Kong Wee; Wong, Fuh Yong; Yap, Yoon Sim; Hartman, Mikael

Outcome after neoadjuvant chemotherapy in Asian breast cancer patients

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Outcome after neoadjuvant chemotherapy in Asian breast cancer patients
  • Contributor: Lim, Li Yan; Miao, Hui; Lim, Joline S. J.; Lee, Soo Chin; Bhoo‐Pathy, Nirmala; Yip, Cheng Har; Taib, Nur Aishah B. M.; Chan, Patrick; Tan, Ern Yu; Lim, Swee Ho; Lim, Geok Hoon; Woo, Evan; Tan, Yia Swam; Lee, Jung Ah; Wong, Mabel; Tan, Puay Hoon; Ong, Kong Wee; Wong, Fuh Yong; Yap, Yoon Sim; Hartman, Mikael
  • imprint: Wiley, 2017
  • Published in: Cancer Medicine
  • Language: English
  • DOI: 10.1002/cam4.985
  • ISSN: 2045-7634
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>We aim to identify clinicopathologic predictors for response to neoadjuvant chemotherapy and to evaluate the prognostic value of pathologic complete response (<jats:styled-content style="fixed-case">pCR</jats:styled-content>) on survival in Asia. This study included 915 breast cancer patients who underwent neoadjuvant chemotherapy at five public hospitals in Singapore and Malaysia. <jats:styled-content style="fixed-case">pCR</jats:styled-content> following neoadjuvant chemotherapy was defined as 1) no residual invasive tumor cells in the breast (ypT0/is) and 2) no residual invasive tumor cells in the breast and axillary lymph nodes (ypT0/is ypN0). Association between <jats:styled-content style="fixed-case">pCR</jats:styled-content> and clinicopathologic characteristics and treatment were evaluated using chi‐square test and multivariable logistic regression. Kaplan–Meier analysis and log‐rank test, stratified by other prognostic factors, were conducted to compare overall survival between patients who achieved <jats:styled-content style="fixed-case">pCR</jats:styled-content> and patients who did not. Overall, 4.4% of nonmetastatic patients received neoadjuvant chemotherapy. The median age of preoperatively treated patients was 50 years. <jats:styled-content style="fixed-case">pCR</jats:styled-content> rates were 18.1% (<jats:styled-content style="fixed-case">pCR</jats:styled-content> ypT0/is) and 14.4% (<jats:styled-content style="fixed-case">pCR</jats:styled-content> ypT0/is ypN0), respectively. <jats:styled-content style="fixed-case">pCR</jats:styled-content> rate was the highest among women who had higher grade, smaller size, estrogen receptor negative, human epidermal growth factor receptor 2‐positive disease or receiving taxane‐based neoadjuvant chemotherapy. Patients who achieved <jats:styled-content style="fixed-case">pCR</jats:styled-content> had better overall survival than those who did not. In subgroup analysis, the survival advantage was only significant among women with estrogen receptor‐negative tumors. Patients with poor prognostic profile are more likely to achieve <jats:styled-content style="fixed-case">pCR</jats:styled-content> and particularly when receiving taxane‐containing chemotherapy. <jats:styled-content style="fixed-case">pCR</jats:styled-content> is a significant prognostic factor for overall survival especially in estrogen receptor‐negative breast cancers.</jats:p>
  • Access State: Open Access